Literature DB >> 1320641

Identification and distribution of the costimulatory receptor CD28 in the mouse.

J A Gross1, E Callas, J P Allison.   

Abstract

T cell activation requires Ag-specific stimulation mediated by the TCR as well as an additional stimulus provided by Ag presenting cells. On human T cells, it has been shown that antibodies to the Ag CD28 can provide a potent amplification signal for cytokine production and proliferation. Here we describe the production of a mAb to the murine homologue of CD28, and the use of this antibody to examine the function and distribution of CD28 in the mouse. Anti-murine CD28 synergizes with TCR-mediated signals to greatly enhance lymphokine production and proliferation of T cells, and the CD28 signal is not blocked by cyclosporin A. In the peripheral lymphoid organs and in the blood of the mouse, all CD4+ and CD8+ T cells express CD28. In the thymus, CD28 expression is highest on immature CD3-, CD8+ and CD4+8+ cells, and on CD4-8- cells that express alpha beta and tau delta TCR. The level of CD28 on mature CD4+ and CD8+ alpha beta TCR+ thymocytes is two- to fourfold lower than on the immature cells. The potent costimulatory function of CD28 on mature T cells, together with the high level of expression on CD4+8+ thymocytes, suggest that this costimulatory receptor might play an important role in T cell development and activation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320641

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  86 in total

1.  Thymocyte apoptosis.

Authors:  Y Yang; J D Ashwell
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

2.  B7 costimulation plays an important role in protection from herpes simplex virus type 2-mediated pathology.

Authors:  Lydia G Thebeau; Lynda A Morrison
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Thymocyte development is normal in CTLA-4-deficient mice.

Authors:  C A Chambers; D Cado; T Truong; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs.

Authors:  Huan Wang; Dongmin Kwak; John Fassett; Lei Hou; Xin Xu; Brandon J Burbach; Thenappan Thenappan; Yawei Xu; Jun-Bo Ge; Yoji Shimizu; Robert J Bache; Yingjie Chen
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

5.  B7 costimulation is critical for antibody class switching and CD8(+) cytotoxic T-lymphocyte generation in the host response to vesicular stomatitis virus.

Authors:  A J McAdam; E A Farkash; B E Gewurz; A H Sharpe
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint.

Authors:  Joy A Williams; Karen S Hathcock; David Klug; Yohsuke Harada; Baishakhi Choudhury; James P Allison; Ryo Abe; Richard J Hodes
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 7.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

8.  Influence of MHC class I molecules on T-cell proliferation induced by CD3 or Thy-1 stimulation.

Authors:  N Amirayan; E Furrie; F Deleuil; A Mellor; L Leserman; P Machy
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

9.  CD4(+) T-cell activation is differentially modulated by bacteria-primed dendritic cells, but is generally down-regulated by n-3 polyunsaturated fatty acids.

Authors:  Susanne Brix; Pia Lund; Tanja M R Kjaer; Ellen M Straarup; Lars I Hellgren; Hanne Frøkiaer
Journal:  Immunology       Date:  2009-11-11       Impact factor: 7.397

Review 10.  Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles.

Authors:  Ryan M Pearson; Joseph R Podojil; Lonnie D Shea; Nicholas J C King; Stephen D Miller; Daniel R Getts
Journal:  Nanomedicine       Date:  2018-10-21       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.